Recently, the life sciences field has seen multiple advances, including new discoveries in disease mechanisms such as Alzheimer’s disease, stroke, and chronic pruritus, as well as cutting-edge achievements in viral structure analysis, innovative drug technology iterations, new organ transplant materials, and basic neurocognitive research. This article focuses on ten major research achievements, comprehensively presenting the latest R&D trends and breakthroughs in biomedicine and life sciences.

---

1. Spatiotemporal dynamics of tau protein diffusion and load changes in Alzheimer’s disease

Recently, the top international geriatric journal Nature Aging published online a major large-sample study in the spatiotemporal dynamics of Alzheimer’s disease (AD) tau. Relying on four independent multicenter cohorts, totaling 2,459 subjects covering the entire disease cycle of normal cognition, mild cognitive impairment, and typical AD dementia, the tau positron emission tomography (tau-PET) data was systematically analyzed. It fills a core cognitive gap in the biomarker system for AD course assessment.

For the first time, the study clearly distinguishes the clinical value of two core indicators: tau spatial diffusion range (SEOT) and traditional standardized uptake ratio (SUVR, representing local tau load): both increase in sync with AD progression, but in ultra-early clinical stages, SEOT’s abnormality detection sensitivity is significantly better than SUVR, allowing pathological abnormalities before obvious cognitive decline can be detected 1~2 years in advance. The study also confirmed that SEOT and SUVR are strongly nonlinear positively correlated with SUVR in the brain’s whole-brain Braak staging, breaking the previous academic assumption of a linear association. The strength of this association is also regulated by gender and APOE ε4 genotype, providing a new dimension for precise risk stratification in the AD population.

Longitudinal follow-up data further revealed the burden-dependent biphasic progression pattern of tau pathology: in the preclinical stage with a low baseline tau load, the rate of spatial spread across brain regions was significantly faster than local load accumulation, whereas after pathology progressed to the dementia stage, the self-aggregation amplification effect of local tau protein dominated, and the rate of load accumulation outpaced spatial diffusion. This achievement establishes SEOT as a core biomarker for early AD screening, complementing SUVR and significantly improving enrollment accuracy and efficacy evaluation efficiency for ongoing anti-tau AD drug clinical trials.

---

2. Qilu Pharmaceutical tops the CDE clinical trial

sponsor rankings for June Yaozhi.com recently officially released the “June 2026 China Clinical Trial Registration Analysis Report.” Based on the current valid registration data publicly disclosed by the CDE, the report provides a panoramic overview of domestic pharmaceutical R&D trends. During this period, a total of 402 new drug clinical trials nationwide completed registration and announcement, with overall R&D activity maintaining a nearly six-month high, and the pace of local innovation pipeline advancement continues to accelerate.

In terms of trial structure, 279 chemical drugs accounted for nearly 70%, making them the absolute mainstream track at the time; There are 139 trials marked as “Other” in the trial phase, accounting for over 30% of total registrations. The vast majority of these are generic drug bioequivalence (BE) trials, directly reflecting the upgrade in the quality of domestic existing generics and the ongoing high prosperity in the high-end complex generic drug sector.

At the single-product level, the new generation analgesic for treating diabetic peripheral neuralgia, merogabalin besylate tablets, topped the popular product list with 8 monthly registrations, highlighting the clustered application characteristics in the sector. On the sponsoring side, Qilu Pharmaceutical ranked first with five clinical registrations covering completely different pipelines, leading the industry in pipeline pipeline advancement efficiency; At the institutional institution level, Sun Yat-sen University Cancer Hospital ranked first with 12 lead new drug trials, highlighting the core bearing role of the leading oncology clinical center; In terms of regional distribution, Shanghai ranks first nationwide with 75 registrations, confirming the R&D and agglomeration advantages of the Yangtze River Delta biopharmaceutical industry cluster.

This month, domestic R&D entered a period of concentrated achievement realization. Core pipelines of local biotech companies such as Baili Tianheng and Kelun Botai successively presented major positive data on top international academic stages. The global competitiveness of domestic innovative drugs continued to rise, and the entire industry was shifting from pipeline expansion to breakthrough in core quality.

3. Xiao Rui’s team at Wuhan University discovered that AQR/SYF1/SYF3 guards the fidelity

of 3′ splicing sites On July 2, Xiao Rui’s research team at Wuhan University Medical Research Institute published original research in the top molecular biology journal Molecular Cell, systematically analyzing the fidelity verification mechanism of the 3′ terminal site of pre-mRNA splicing in mammals for the first time, opening a new direction for studying the pathogenic mechanisms of inflammatory bowel disease (IBD).

Recognition of 3′ splicing sites (3’ss) in eukaryotic pre-mRNA is a core step in variable splicing regulation, but the conservation of 3’ss sequences in mammalian genomes is much lower than in lower eukaryotes. The U2AF heterodimer, responsible for recognizing 3’ss, naturally has high recognition fault tolerance, and previous studies have not clarified the core pathway for in vivo specific correction of non-classical 3’ss misrecognition. The team identified the core splicer components AQR (DExH family RNA helibase), SYF1, and SYF3 as the synergistic 3’ss fidelity guardian factor during the pre-catalytic spliceosome B complex assembly stage, actively dissociating weakly matched pseudo-3’s ss from U2AF misconjugation, and preventing abnormal splicing from entering the catalytic process.

Functional validation showed that after knockdown of the above factor expression, a large number of frameshift-type abnormal 3′ splicing products appeared in the entire transcriptome, triggering misfolded protein accumulation and toxic stress of unfolded proteins. In mouse intestinal epithelial conditional knockout models, it spontaneously induced mucosal barrier damage and chronic enteritis phenotypes, with transcriptomic features highly consistent with clinically active IBD samples. This study breaks through previous research on splicing fidelity, establishing for the first time a direct association between abnormal splicing accumulation and chronic intestinal inflammation, providing a new target direction for innovative drug development with novel diagnostic markers for IBD and targeted splicing regulation.

4. The Zhejiang University team discovered that the hydrogel “local sentinel” can resist rejection and repair tissues

Recently, a joint team from Xie Haiyang, Wang Hangxiang, and Zheng Shusen from Zhejiang University published a major original achievement in the top materials journal Advanced Science, launching an immunomodulatory hydrogel (iGEL) with dual functions of anti-rejection and tissue repair, providing a brand-new solution for clinical challenges in local immune regulation after organ transplantation.

Currently, systemic immunosuppression regimens are commonly adopted after organ transplantation, with shortcomings such as drug bioavailability below 10% and difficulty in meeting local drug concentration targets in grafts. Long-term medication administration can also induce excessive suppression of systemic immunity, greatly increasing the risk of opportunistic infections and secondary tumors. Moreover, existing immunotherapies lack the ability to repair in situ tissue, posing significant technical bottlenecks in improving long-term graft survival rates.

This innovative platform deeply couples prodrug engineering technology with the design of inflammation-restricting pharmacokinetics, utilizing a minimally invasive dual syringe device to achieve autonomous post-subcutaneous delivery and forming a stable in situ drug reservoir based on excellent tissue adhesion: it triggers targeted drug release only in the highly inflammatory microenvironment after transplantation, simultaneously exporting anti-rejection active molecules and tissue regeneration factors. In the mouse allogeneic skin transplantation model, the iGEL treatment group downregulated local effector T cell infiltration by 72%, increased angiogenesis efficiency by 2.8 times, successfully remodeled the microenvironmental balance between immune tolerance and tissue regeneration, and extended the survival time of skin grafts by more than three times compared to the traditional systemic drug group. Industry insiders point out that this pathologically responsive local treatment platform can quickly expand to scenarios such as coating drug delivery for solid organ transplants and repair of refractory autoimmune damage, with the potential to reconstruct the post-transplant immune management pathway.

5. Nature: Maintaining the brain’s spontaneous repair system to promote stroke recovery

. Recently, the Tokyo Institute of Scientific Research, Japan, together with several research institutions, published breakthrough findings in the regulation of endogenous stroke repair in Nature, providing a novel target pathway to address the clinical pain point of extremely narrow recovery windows for stroke patients worldwide.

As the leading cause of long-term disability among adults worldwide, current clinical interventions for stroke heavily rely on intravenous thrombolysis within 4.5 hours of onset and intravascular thrombectomy within 24 hours. Over 90% of patients miss the window and cannot receive effective treatment. Previously, there was no clear explanation of why the brain’s spontaneous repair ability remains silent for several weeks after injury.

This study confirms for the first time that zinc finger transcription factor ZFP384 is the core negative regulatory switch of this process: after stroke, ZFP384 expression in perifocal microglia is upregulated in sync with repair function decline. By remodeling chromatin through three-dimensional interactions, it directly inhibits transcription of core functional genes related to microglia repair phenotypes and downregulates the secretion of key neurotrophic repair factors such as IGF1. Ultimately, microglia lose their ability to repair tissue.

Animal experiments show that the therapeutic antisense oligonucleotide ASO-Zfp384 targeting Zfp384 can specifically knock down the expression of this molecule in microglia, maintain long-term expression of repair-related genes, and even after administration three weeks after stroke injury in model mice, it can still significantly improve long-term neurological prognosis. Clinical sample validation showed that the expression of human homologous ZNF384 was significantly negatively correlated with IGF1 levels in brain tissue of stroke patients, supporting the clinical relevance of this evolutionary conservation pathway. The team has already initiated compliance assessments for candidate scientists and is about to advance clinical trials, which is expected to expand the effective stroke intervention window from the current hours to weeks, significantly reducing the burden of stroke-related disabilities.

6. Aging mediates mechanical touch-induced itching

through serotonergic signaling mediation through 5-HT₇ receptors. Addressing the pain point of a high incidence in middle-aged and elderly patients in clinical settings with long-term lack of precise intervention targets for idiopathic chronic mechanical itch without clear skin lesions, Recently, a domestic pain neurobiology team has made original achievements in the field of serotonergic itch pathway research, clarifying for the first time the core mechanism by which aging is mediated by 5-HT₇ receptor subtype-specific signal upregulation and drives mechanical touch-induced itch sensitization, filling a gap in research on the mechanism of age-related hypersensitivity to itch.

The study used young (23 months old) and elderly (1820 months) male C57BL/6J mice matched in age gradient as model organisms, and systematically analyzed them using quantitative behavioral detection, in vivo calcium imaging, single-cell transcriptome validation, and a multi-pathway pharmacological intervention system. Results confirmed that the threshold for mechanical itch induction in elderly mice dropped by more than 45% compared to the younger group, and the overall exposure level of 5-HT in urine was significantly increased. Neural localization studies show that the expression of 5-HT₇ receptors in diameter sensory neurons and projection neurons in the dorsal angle III-IV layers of the dorsal angle in elderly mice is more than 2.3 times higher than in the younger group.

Pharmacological validation further confirmed: systemic or intrathecal targeted blockade of 5-HT₇ receptors can completely reverse the pruritic hypersensitivity phenotype in aged mice, with antipruritic effects lasting over 90 minutes, whereas 5-HT₃ receptor antagonists only show weak antipruritic effects when administered locally, with no significant activity in systemic intervention. This study provides direct preclinical evidence for the development of first-in-kind new drugs for age-refractory chronic pruritus. The team also mentioned the current limitations of using urine 5-HT as an indirect marker for peripheral exposure. Later, the dynamic validation system for the pathway will be further refined through in vitro microdialysis technology. The full study is published in a sub-journal of the top international neuroscience journal Pain.

7. Two research groups from Shanghai Jiao Tong University jointly report on new strategies

for inducing protein degradation. Recently, the research teams of Shen Yudao and Zhao Bo from the School of Pharmacy, Shanghai Jiao Tong University, have jointly achieved a breakthrough in foundational technology in the field of targeted protein degradation, officially launching the brand-new induced protein degradation platform RIMTAC. It provides a differentiated R&D path for the PROTAC track, which has long been constrained by E3 ligand resource bottlenecks.

Currently, global PROTAC R&D has entered a critical stage of commercialization, with over 20 candidate molecules advancing into clinical trials. The world’s first AR PROTAC drug, ARV-471, was recently approved for market launch. The sector’s market momentum continues to rise, but the core shortcomings remain unresolved: E3 ubiquitin ligand adaptation ligands available for PROTAC design are extremely limited, accounting for nearly 40% of existing clinical pipelines as VHL-dependent degraders. Common issues commonly exist such as poor membrane permeability of natural VHL ligands, rapid clearance in vivo, and substandard pharmacokinetic properties, which severely limit drug potential.

The newly released RIMTAC technology breaks away from the traditional PROTAC design logic by efficiently conjugating the target protein to VHL E3 ligase through an indirect mediation mode, eliminating the need to introduce the original VHL small molecule ligand. The research team has designed and synthesized a series of RIMTAC molecules targeting core disease targets BRD4, AKT, and JAK1. Multiple lead compounds achieve near-complete degradation of target proteins at the cellular level, and systematic validation has confirmed that their degradation process strictly depends on the ubiquitin-proteasome pathway.

This technology not only completely avoids the drug shortcomings of traditional VHL ligands but also innovatively retains the physiological functions of endogenous tumor suppressor factors in VHL, enabling simultaneous synergistic therapeutic effects of target protein degradation and VHL pathway activation. It greatly expands the toolbox for targeted protein degradation technology and provides a new approach for first-in-class drug development for malignant tumors and inflammatory autoimmune diseases. Currently, related research has received support from multiple national research grants.

8. Collaborative research on chemical defense and resource acquisition strategies in root systems at the Chengdu Institute of Biology has made progress

The latest research results from the research team led by Yin Huajun at the Chengdu Institute of Biology, Chinese Academy of Sciences, were recently published in the top international botanical journal New Phytologist. For the first time, the chemical defense functions of roots were incorporated into the theoretical framework of root economic spatial theory, filling a long-standing gap in the field of functional traits in underground plants.

For a long time, research on resource allocation and balancing in plant ecology and medicinal plant R&D has focused on aboveground organs. The co-evolution mechanisms of root resource acquisition strategies and chemical defense systems have always been core blind spots and have become theoretical bottlenecks restricting breakthroughs in applications such as rhizosphere microbial interaction regulation, stress-resistant plant breeding, and restoration of degraded ecosystems.

Yin Huajun’s team used 13 coexisting dominant tree species in the original forest area of Motuo, Tibet, as natural research subjects, and conducted systematic validation around two core differentiation dimensions of root economic space: “conservation–acquisition” and “autonomy–outsourcing”: The study confirmed that conservative and autonomous roots have significantly higher diversity and uniformity in defense metabolites, while the colonization levels of root pathogenic fungi are significantly reduced; In contrast, high-yield root systems have evolved defense pathways specifically enriched with terpenes and nitrogen-containing alkaloid functional metabolites, forming a synergistic adaptation strategy for functional differentiation.

This achievement marks a landmark progress in the team’s construction of an original theoretical framework for “rhizosphere functional traits,” expanding the cognitive boundaries of plant ecological adaptation strategies and providing new guidance for industrial applications such as targeted regulation of root metabolism in medicinal plants and species allocation for plateau vegetation restoration.

9. The Institute of Biophysics, Chinese Academy of Sciences, discovered the mechanism

of active change in perceptual sensitivity during attention transfer On July 14, the research group led by Mr. He at the Institute of Biophysics, Chinese Academy of Sciences, published original research results online on June 30 in the Proceedings of the National Academy of Sciences (PNAS), systematically revealing for the first time a new mechanism of active regulation of brain perceptual sensitivity during implicit attention transfer, filling a key gap in cognitive neuroscience research on the underlying logic of attention operation.

For a long time, research in this direction has faced two major core technical bottlenecks: millisecond-level implicit attention shift time windows are extremely difficult to precisely anchor, and the measurement of dynamic changes in perceptual sensitivity is easily mixed with passive perception attenuation and eye-movement associated disturbances, resulting in the academic community never clarifying the true response patterns of perception systems during attention resource reallocation.

Relying on years of expertise in attention oscillation research, He Sheng’s team accurately pinpointed a narrow time window of several hundred milliseconds when attention is about to shift by predicting phase characteristics of low-frequency attention rhythms. They inserted neutral and irrelevant detection stimuli with gradient contrast into this window, simultaneously collecting pupil dynamic responses, functional MRI, and intracranial nerve signals, achieving quantitative, non-interference measurement of changes in perceptual sensitivity
The research team ultimately confirmed that at the moment of implicit attention shift, the brain actively downregulates the visual sensitivity of the original attention field by 15%~20%. This inhibitory effect originates from passive signal attenuation in higher attention cortexes such as the parietal lobe, rather than in the primary visual cortex, and is an inherent program built into attention neural networks. This conclusion breaks the traditional theoretical model of “smooth redistribution of attention resources,” demonstrating that “active predictive perception regulation” is a common feature of the brain’s multi-level cognitive systems, providing a new core basis for screening intervention targets for neurological diseases such as ADHD and for precise decoding of attention states in brain-computer interfaces.

END

---

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: meritsip@meritsandtree.com

© 2025 MeritsIP. All Rights Reserved.